Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

BridgeBio Pharma (BBIO) Return on Capital Employed (2019 - 2025)

BridgeBio Pharma's Return on Capital Employed history spans 7 years, with the latest figure at 0.77% for Q4 2025.

  • For Q4 2025, Return on Capital Employed rose 16.0% year-over-year to 0.77%; the TTM value through Dec 2025 reached 0.77%, up 16.0%, while the annual FY2025 figure was 0.82%, 21.0% up from the prior year.
  • Return on Capital Employed for Q4 2025 was 0.77% at BridgeBio Pharma, down from 0.74% in the prior quarter.
  • Across five years, Return on Capital Employed topped out at 0.53% in Q2 2021 and bottomed at 1.33% in Q4 2023.
  • The 5-year median for Return on Capital Employed is 0.82% (2022), against an average of 0.86%.
  • The largest annual shift saw Return on Capital Employed tumbled -41bps in 2023 before it soared 43bps in 2024.
  • A 5-year view of Return on Capital Employed shows it stood at 0.76% in 2021, then fell by -22bps to 0.92% in 2022, then tumbled by -44bps to 1.33% in 2023, then surged by 30bps to 0.93% in 2024, then increased by 17bps to 0.77% in 2025.
  • Per Business Quant, the three most recent readings for BBIO's Return on Capital Employed are 0.77% (Q4 2025), 0.74% (Q3 2025), and 0.82% (Q2 2025).